The Development and Evaluation of Pan-Coronavirus Vaccines
Project Number1P01AI168347-01
Contact PI/Project LeaderDIAMOND, MICHAEL S Other PIs
Awardee OrganizationWASHINGTON UNIVERSITY
Description
Abstract Text
Overall Summary
Given the historical outbreaks of coronaviruses, coupled with the recent emergence of SARS-
CoV-2 and the destabilizing consequence of COVID-19 on global health and economy, there is
an urgent and critical need to develop new vaccines capable of broad protection against existing
and future Sarbecoviruses and Merbecoviruses. This P01 program project (PPG) addresses
the hypothesis that a combination of evolutionarily-designed and optimized B and T cell
antigens can confer broad and protective immunity against Sarbecoviruses and
Merbecoviruses that currently exist or could emerge from zoonotic reservoirs. The PPG
integrates the work of eleven leading laboratories with records of collaboration that have expertise
in coronavirus biology, viral pathogenesis, B and T cell immunity, vaccine development, animal
challenge studies, structural biology, antibody structure and function, antigen design, and
evolutionary analysis of viruses. All Projects and Cores plan interactive studies with the focused
goal of designing optimized B and T cell antigens for incorporation in adenoviral (ChAd) and
vesicular stomatitis virus (VSV) vectors to create mucosal and systemic vaccines that protect
against infection and disease caused by a range of coronaviruses of potential concern. The PPG
is served by a central Animal Challenge Core that performs vaccination and infection
experiments in mice and hamsters and a central Administrative Core that streamlines data
management and sharing, provides computational analysis for down-selection and scientific
decision-making, and facilitates communication. Our proposal and antigen design program serves
as a blueprint for possible product development with ChAd vaccines, VSV-based vaccines, or
even with other platforms (e.g., mRNA vaccines, nanoparticles, etc.) not directly evaluated here.
By the conclusion of our PPG, we envision generating at least one and likely multiple viral-
vectored vaccine platforms that induce broad spectrum immunity to multiple coronaviruses of
concern including human and zoonotic Sarbecoviruses and Merbecoviruses that could emerge in
the future.
Public Health Relevance Statement
Overall Narrative
Our proposal aims to develop viral-vectored vaccines that induce broad-spectrum B and T cell
immunity to Sarbecoviruses and Merbecoviruses with pandemic potential that could emerge from
zoonotic reservoirs.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
068552207
UEI
L6NFUM28LQM5
Project Start Date
02-September-2022
Project End Date
31-August-2025
Budget Start Date
02-September-2022
Budget End Date
31-August-2025
Project Funding Information for 2022
Total Funding
$7,990,794
Direct Costs
$6,472,678
Indirect Costs
$1,518,116
Year
Funding IC
FY Total Cost by IC
2022
National Institute of Allergy and Infectious Diseases
$7,990,794
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1P01AI168347-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1P01AI168347-01
Patents
No Patents information available for 1P01AI168347-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1P01AI168347-01
Clinical Studies
No Clinical Studies information available for 1P01AI168347-01
News and More
Related News Releases
No news release information available for 1P01AI168347-01
History
No Historical information available for 1P01AI168347-01
Similar Projects
No Similar Projects information available for 1P01AI168347-01